Hepatitis C other diagnostic studies: Difference between revisions
Varun Kumar (talk | contribs) Created page with "{{Hepatitis C}} {{CMG}} {{EJ}} ==References== {{Reflist|2}} C Category:Gastroenterology Category:Infectious disease {{WH}} {{WS}}" |
Varun Kumar (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Hepatitis C}} | {{Hepatitis C}} | ||
{{CMG}} | {{CMG}}; {{AOEIC}} {{VK}} | ||
== Recommendations for Utility of the Liver Biopsy and Noninvasive Tests of Fibrosis: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>== | |||
{{cquote| | |||
'''1.''' A liver biopsy should be considered in patients with chronic hepatitis C infection if the patient and health care provider wish information regarding fibrosis stage for prognostic purposes or to make a decision regarding treatment ''(Class IIa, Level B)'' | |||
'''2.''' Currently available noninvasive tests may be useful in defining the presence or absence of advanced fibrosis in persons with chronic hepatitis C infection, but should not replace the liver biopsy in routine clinical practice (''Class IIb, Level C)''.}} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 22:30, 21 February 2012
|
Hepatitis C |
|
Diagnosis |
|
Treatment |
|
Hepatitis C other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Hepatitis C other diagnostic studies |
|
Risk calculators and risk factors for Hepatitis C other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
Recommendations for Utility of the Liver Biopsy and Noninvasive Tests of Fibrosis: AASLD Practice Guidelines 2009[1]
| “ |
1. A liver biopsy should be considered in patients with chronic hepatitis C infection if the patient and health care provider wish information regarding fibrosis stage for prognostic purposes or to make a decision regarding treatment (Class IIa, Level B) 2. Currently available noninvasive tests may be useful in defining the presence or absence of advanced fibrosis in persons with chronic hepatitis C infection, but should not replace the liver biopsy in routine clinical practice (Class IIb, Level C). |
” |
References
- ↑ Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter
|month=ignored (help)